Protagonist Therapeutics
Protagonist is a California peptide company whose hepcidin mimetic rusfertide controls the excess red cell production of polycythaemia vera without repeated phlebotomy, with positive phase 3 VERIFY results in 2025 and a partnership with Takeda.
Overview
Protagonist Therapeutics, listed on Nasdaq, designs peptide medicines. Rusfertide, an injectable mimetic of the iron hormone hepcidin, restricts iron available for red cell production and in the phase 3 VERIFY trial reduced the need for phlebotomy in polycythaemia vera, a chronic myeloproliferative blood cancer; Takeda licensed the drug in 2024. The company's other lead, the oral IL-23 receptor antagonist icotrokinra, is partnered with Johnson & Johnson in psoriasis. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Scorecard
All companies- approved products +6
- modalities +2
- regions +1
- registry trials +5
Similar pages
not linked directly; found by shared links- CompanyHeidelberg Pharma
Shares Takeda and the tag ctgov-sponsor.
- CompanyAscentage Pharma
Shares Takeda and the tag ctgov-sponsor.